Peptides represent one of the most promising frontiers in modern medicine and integrative therapeutics. From regenerative applications to neuroendocrine modulation and longevity science, their biological precision offers powerful clinical potential. Yet as peptide use expands, so do critical questions about quality, sourcing, verification, and regulatory oversight.
Peptide Safety and Integrity is a comprehensive white paper designed to bring clarity to this rapidly evolving landscape. This publication examines the global peptide supply chain, explains the difference between a Certificate of Analysis and true analytical verification, and outlines why purity claims alone do not guarantee molecular identity or safety. It also addresses the clinical implications of fragmented peptides, immunogenic risk, injectable safeguards, and the important legal distinctions between FDA-approved drugs, compounded products, and research-use-only materials.
Written for healthcare providers, informed consumers, and policymakers alike, this paper moves beyond theory to emphasize responsible oversight, analytical rigor, and governance. It offers practical guidance, including a clinician safety framework to help ensure that peptide use aligns with both scientific integrity and patient protection.
In a market where labeling can be misleading and regulatory boundaries are often misunderstood, this white paper provides a disciplined, evidence-informed perspective on how peptides should be sourced, verified, and utilized. by Mark L. Gordon, MD
11 Pages 30 References
